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Objective: To assess the microbial growth in unfortified and fortified Holder pasteurized donor 
human milk (HPDHM) during 96 hours of refrigerated storage in a clinical setting. 
Methods: Thirty-six unfortified samples and 77 fortified samples of HPDHM were prepared in a 
neonatal intensive care milk preparation room and stored in the NICU refrigerator at 4°C to 
simulate a real-life feeding environment. One milliliter aliquots were removed at 24-hour 
intervals and cultured in duplicate for bacterial growth on solid blood agar medium. Viable 
bacterial colonies were characterized using standard microbiological methods. Results: 96.5% of 
milk samples manipulated in a vertical laminar flow hood were negative for bacterial growth. In 
the remainder 3.5% of the samples, the maximum growth was 1 colony forming unit/0.1 ml 
plated. Higher colony counts were observed when the laminar hood was not used. In all cases, 
the colonies represented common skin bacteria and demonstrated an inconsistent and unsustained 
growth. Fortifier status and storage time were not significantly associated with increased 
bacterial growth (P > 0.05). Conclusions: Unfortified and fortified HPDHM remain largely free 
of bacterial growth for up to 96 hours of refrigerated storage in NICU settings. Sample handling 
techniques are important for preventing microbial contamination. 
 





What Is Known 
• Unfortified Holder pasteurized donor human milk remains free of microbial growth for 
up to 96 hours of refrigerated storage in a laboratory setting. 
• Neonatal intensive care units in the United States routinely fortify human milk for very 
low birth weight infants. 
What Is New 
• Unfortified and fortified Holder pasteurized donor human milk remains largely free of 
microbial growth for up to 96 hours of refrigerated storage in a neonatal intensive care 
unit setting, with appropriate handling protocols. 
• Growth is sporadic in nature, represents common skin bacteria, and does not increase 
with time. 
 
Mother's milk is the ideal source of nutrition for premature infants, providing benefits in host 
defense, gastrointestinal maturation, infection rate, neurodevelopmental outcomes, and long-term 
cardiovascular and metabolic disease (1). The American Academy of Pediatrics (AAP) 
recommends that mother's own milk, fresh or frozen, appropriately fortified, should be the 
primary diet of enteral feeds for very low birth weight (VLBW) infants (2). If mother's own milk 
is unavailable, despite significant lactation support, pasteurized donor milk is considered the 
most physiologic alternative (2–4). 
 
The use of donor milk in United States neonatal intensive care units (NICUs) is increasing, with 
over 65% of level 3 and level 4 NICUs reporting some use in a 2015 Center for Disease Control 
survey (5). The Human Milk Banking Association of North America (HMBANA) recently 
extended their refrigerated storage recommendations for Holder pasteurized donor human 
milk (HPDHM) from 24 to 48 hours, based primarily on evidence of the storage of unfortified 
HPDHM (6–9). 
 
Fortification of human milk for the preterm infant is recommended by the AAP (2) and is 
common practice in the United States, with over 90% of NICUs reporting that they use human 
milk fortifiers (5). A 2018 literature review on the refrigerated and frozen storage of HPDHM 
found only a single study that had assessed storage of fortified HPDHM (10). Given that HPDHM 
is routinely fortified for preterm infants, the objective of this study was to assess microbial 
growth in both unfortified and fortified HPDHM over 96 hours of refrigerated storage in “real 
life” NICU settings. We hypothesize that unfortified and fortified HPDHM, because of inherent 
antimicrobial properties, will maintain microbiological purity for 4 days of 




This was an observational, descriptive study designed to determine the bacterial content in 
HPDHM after extended storage for 96 hours at 4oC in a human milk refrigerator for all patients 
located in a level IV NICU. The study was approved by the IRB at New York Medical College 
and Westchester Medical Center. 
 
All neonates with birth weight ≤1500 g and gestational age (GA) ≤32 weeks, patients with 
congenital gastrointestinal (GI) or cardiac anomalies, and patients recovering from NEC receive 
exclusive human milk diets (EHM). An EHM consists of mothers expressed breast milk 
(EBM), donor milk (when EBM is unavailable), and fortification with a human milk-derived 
fortifier, which is added when the patient is tolerating 80 mL · kg−1 day−1 of enteral feeds and 
adjusted based on the patient's growth. This diet is maintained until 34 weeks corrected GA after 
which we switch to a bovine milk-derived fortifier, and donor milk is replaced with preterm 
formula. All other infants receive preterm or term formula as a supplement or full diet and EBM 
is fortified with a bovine milk fortifier. 
 
Samples were collected at Maria Fareri Children's Hospital (Valhalla, NY), in a dedicated human 
milk preparation room by a trained milk technician. Bottles of HPDHM were obtained from the 
New York Milk Bank (Valhalla, NY), licensed by the New York State Department of Health and 
accredited by HMBANA. HPDHM is dispensed from HMBANA banks only if 
postpasteurization cultures demonstrate no bacterial growth. The milk arrives at hospitals frozen 
and is stored in the freezer at −20oC until needed. In this study, 100 mL bottles of HPDHM were 
thawed per our NICU protocol and aliquoted for individual patients daily. If indicated, 
fortification was done using human milk-derived human milk (HUM) fortifier (Prolacta 
Bioscience, City of Industry, CA) or bovine-derived (BOV), sterile human milk fortifier 
(Enfamil Human Milk Fortifier Acidified Liquid, Mead Johnson, Chicago, IL). HPDHM 
was fortified either in the fortifier manufacturer's container (Prolacta), sterile specimen cups 
(Sterile Specimen Container, Medegen Medical Products), or aseptic airtight, leak-resistant 
containers (Snappies, Mead Johnson, Chicago, IL), depending on the volume needed. Clean 
techniques were used when preparing infant feeds including: practicing hand hygiene; wearing 
clean gowns, caps, masks, and gloves; disinfecting counters; and using measuring containers, 
which are supplied in sealed sterile packages. 
 
Prepared HPDHM was stored at 4oC in the NICU refrigerator. In the first 24 hours, every 3-4 
hours nurses removed milk for feedings using a sterile syringe and fresh gloves. After the 
feeding removal, unused HPDHM was placed back in the refrigerator until the next feeding. 
HPDHM containers were accessed 6 to 8 times on average by 2 or 3 different nurses in the first 
24 hours of storage. After 24 hours in the refrigerator, HPDHM was considered “expired” for 
clinical use. For the study, the first 1 mL sample, designated as time 0, was removed 
immediately after preparation of the HPDHM using a sterile syringe and clean gloves and placed 
into a sterile study container for transfer to the microbiology laboratory. Beyond the 24-hour 
refrigeration, the bottles of “expired” HPDHM continued to be stored in the NICU refrigerator 
for 4 days in a locked, fenestrated box to ensure exposure to the same storage environment. 
Bottles were accessed only for the purpose of drawing additional study samples. One milliliter 
samples were removed at 24, 48, 72, and 96 hours. Each sample was removed using a new sterile 
syringe, sterile gloves, and placed in a sterile container. During the study time (96 hours), it was 
estimated that the milk room refrigerator was opened dozens of times daily by different nurses. 
The milk room countertop was disinfected at each step of milk handling. 
 
All samples were transported to a Biosafety Level 2 (BSL-2) microbiology laboratory in sterile 
containers in a cooler for plating on standard (5%) Sheep's Blood Agar medium. The study is 
divided into 2 phases based on the movement of the microbiology lab, which resulted in the use 
of 2 different microbiological approaches. In the first, samples were plated on a freshly 
disinfected laboratory benchtop (BENCH) employing standard aseptic microbiological 
techniques. In the second, samples were plated inside a biosafety cabinet equipped with vertical 
laminar airflow (LAMINAR) to eliminate background contamination. 
 
Samples were cultured in duplicate per HMBANA guidelines. Briefly, 0.1 ml of HPDHM was 
placed on plates that were then incubated for 48 hours at 34°C. The number of colonies grown on 
each plate was enumerated by a colony counter. Cultures were classified based on the number of 
CFUs per the HMBANA standard operating procedure of: 0 (accept); 1 to 5 CFUs (retest); 6+ 
(reject). Colonies were characterized by morphology, hemolytic pattern, Gram-staining, cellular 
morphology, and pertinent biochemical tests. To ensure that the microbiological laboratory 
environment, or the sheep blood agar plates themselves were not contributing to the number of 
growing bacterial colonies in these experiments, 2 control plates were “mock” plated without 
milk using a sterile disposable spreader and incubated along with the milk samples. 
 
Statistical analysis was performed using SAS 9.4 Enterprise Edition (SAS Software, Cary, 
NC). P value 0.05 or less was considered statistically significant. Samples were categorized by 
the number of timepoints that showed any growth (timepoint 0–4; growth = yes/no). Differences 
in categorical data were evaluated using a Fisher exact test. A mixed model was used to analyze 
repeated measures of the same sample for the main effects of time (0, 24, 48, 72, and 96 hours) 




The 113 bottles of HPDHM included in this study reflect the clinical need based on our census 
and established feeding protocol. When sporadic bacterial growth was observed in BENCH 
samples, timepoint 0 was added to the study protocol to determine if bacteria were introduced 
into the HPDHM by the milk technician. Therefore, each bottle had between 4 (when timepoint 0 
was not done) and 5 timepoints, for a total of 521 timepoints assessed. Baseline data (at time 0) 
was not available for 44 of the samples collected during BENCH culturing. As stated previously, 
each timepoint was cultured in duplicate (except for 2 time points), for a total of 1040 test 
cultures, along with 80 background control cultures. BENCH culturing, which occurred between 
June and August 2016, included 73 bottles of HPDHM, and LAMINAR culturing, which 
occurred in January 2017, included 40 bottles. Table 1 contains a summary of the study samples. 
 
Table 1. Summary of types of Holder pasteurized donor human milk included in the study 
Type of HPDHM June to August 2016 January 2017 
No. HPDHM samples 73 40 
No. timepoints 321 200 
No. culture 640 400 
Biosafety level of culture Lab and plating environment BSL-2 disinfected benchtop BSL-2 laminar hood 
Unfortified samples 16 (22%) 20 (50%) 
HUM fortified samples 55 (75%) 0 (0%) 
BOV fortified samples 2 (3%) 20 (50%) 
BOV = bovine-derived fortifier; BSL = biosafety level; HPDHM = Holder pasteurized donor human milk; HUM = 
human-derived fortifier. 
 
Results by Lab Environment 
 
Forty-two percentage (47/113) of the samples had no cultures exhibiting growth at any 
timepoint, 29% (33/113) had growth in 1 timepoint, 12% (13/113) had growth in 2 timepoints, 
12% (13/113) had growth in 3 timepoints, and 6% (7/113) had growth in 4 timepoints. There was 
no growth observed in control samples. Of the 519 timepoints cultured in duplicate, 76% 
(395/519) had no growth in either culture, 7% (36/519) had growth in 1 of the 2 plates, and 17% 
(88/519) had growth in both plates. Results were compared between BENCH and LAMINAR 
because of the different plating environments. There was a significant difference (P < 0.0001) in 
the prevalence of samples that had no growth at any time point between BENCH (20/73, 27.4%) 
and LAMINAR (27/40, 67.5%). BENCH had a higher rate of samples with 2 or more timepoints 
exhibiting growth than LAMINAR (32/73, 43.8% vs 1/40, 2.5%; P < 0.0001). 
 
 
Figure 1. Heat map of duplicate cultures at 0, 24, 48, 72, and 96 hours for 113 samples of Holder 
pasteurized donor human milk. BENCH—data represent 73 samples collected between June and 
August 2016 and cultured on a disinfected benchtop in a BSL-2 lab. LAMINAR—data represent 
40 samples collected during January 2017 and cultured in a laminar flow cabinet in a BSL-2 lab. 
CFU—colony forming unit per 0.1 mL of sample; black shading—no data available. Each line 
represents a sample in duplicate over time. 
 
There were 0 CFUs in 85% (885/1040) of the cultures tested. Eleven percentage (118/1040) of 
cultures grew 1 to 5 CFUs, and 4% (37/1040) of cultures grew 6 or more CFUs. Only 1/113 
(0.09%) samples grew 6 or more CFUs on all cultures at all timepoints. One sample (0.09%) 
grew 6 or more CFUs on duplicate cultures at 3 time points. And 1/113 (0.09%) sample grew 6 
or more CFUs on duplicate cultures at 2 time points. There was a significant difference (P < 
0.001) in the percentage of cultures exhibiting any growth between BENCH (141/640, 22.0%) 
and LAMINAR (14/400, 3.5%). A heat map representing all study cultures by phase is presented 
in Figure 1. 
 
To determine if the laboratory environments were associated with different outcomes, we 
performed a sub-analysis on only the unfortified samples. Overall, there were 344 cultures from 
unfortified HPDHM and 11% (37/344) exhibited growth. The prevalence of unfortified cultures 
exhibiting growth in BENCH was 20% (29/144) compared with 4% (8/200) in LAMINAR, 
which was statistically significant (P < 0.0001). 
 
Microbiological identification was done on 40 representative colonies, based on Gram stain, 
morphology, hemolysis, catalase test, mannitol test, TSI test: 30/40 (75%) colonies 
grew Staphylococcus epidermidis. Six of 40 (15%) colonies grew Staphylococcus aureus. Four 
of 40 (10%) colonies grew Gram-positive/variable Bacilli. No Gram-negative organisms were 
identified. 
 
Effects of Fortifiers 
 
The 2 different culture environments (BENCH vs LAMINAR) were also associated with the use 
of different fortifier types (neutral HUM vs acidic BOV), therefore, the primary comparison we 
made was between unfortified and fortified samples within each unique culture environment 
(Table 2). Within BENCH, there was no difference in the distribution of samples by the number 
of timepoints with growth between fortified and unfortified samples (P =0.7035). The percentage 
of samples with 2 or more timepoints exhibiting any growth was 43.8% (25/57) for fortified 
samples and 43.8% (7/16) for unfortified samples. There was a statistically significant difference 
between the unfortified and fortified BENCH samples in the distribution of cultures by CFU 
classification (P = 0.0029), with unfortified samples having a higher prevalence of cultures with 
6+ CFUs (discard) (10.4% vs 4.4%, respectively) and a lower prevalence of cultures containing 1 
to 5 CFUs (retest) (9.7% vs 18.2%, respectively). Within LAMINAR samples, there was no 
difference in the distribution of samples by the number of timepoints containing any growth (P = 
0.3008) or the distribution of cultures by CFU classification (P = 0.7868) between fortified and 
unfortified samples. There was no growth in 96.5% of the cultures in LAMINAR, and the 
maximum growth on any 1 culture was 1 CFU. Additionally, all cultures that showed growth in 
the LAMINAR environment had no growth on their duplicate culture plates. These results are 
summarized in Table 2. 
 
Effects of Time Within Phases 
 
The proportion of samples exhibiting any growth at each 24-hour interval is summarized 
in Table 3 by culture technique. There was no observed difference in samples with any growth 
by time for either fortified or unfortified samples in BENCH or LAMINAR (P > 0.24). When 
assessing the number of CFUs per culture using a repeated measures analysis to account for 
multiple cultures over 96 hours, neither time nor fortifier status were significant for BENCH or 
LAMINAR (P > 0.05). 
 
Table 2. Proportion of samples by number of timepoints with any growth, and number of 
cultures by range of colony forming units within each study phase 
 Unfortified Fortified P value 
BENCH    
No. HPDHM samples (73 total) 16 57  
Samples by number of timepoints with growth   0.7035 
0 timepoints w/ growth 6 (37.5) 14 (24.6)  
1 timepoint w/ growth 3 (18.8) 18 (31.6)  
2 timepoints w/ growth 2 (12.5) 10 (17.5)  
3 timepoints w/ growth 4 (25.0) 9 (15.8)  
4 timepoints w/ growth 1 (6.3) 6 (10.5)  
Number of cultures (640 total) 144 496  
Number of cultures by number of CFUs   0.0029 
0 CFUs (accept) 115 (79.9) 384 (77.4)  
1 to 5 CFUs (retest) 14 (9.7) 90 (18.2)  
6+ CFUs (reject) 15 (10.4) 22 (4.4)  
LAMINAR    
No. HPDHM samples (40 total) 20 20  
Samples by number of timepoints with growth   0.3008 
0 timepoints w/ growth 12 (60.0) 15 (75.0)  
1 timepoint w/ growth 8 (40.0) 4 (20.0)  
2 timepoints w/ growth 0 (0.0) 1 (5.0)  
3 timepoints w/ growth 0 (0.0) 0 (0.0)  
4 timepoints w/ growth 0 (0.0) 0 (0.0)  
No. cultures (400 total) 200 200  
No. cultures by number of CFU   0.7868 
0 CFUs (accept) 192 (96.0) 194 (97.0)  
1 to 5 CFUs (retest) 8 (4.0) 6 (3.0)  
6+ CFUs (reject) 0 (0.0) 0 (0.0)  
Date represent quantities (%) of samples and cultures with growth. Differences in categorical classifications were 
evaluated using a Fisher exact test. BENCH represents samples cultured on a disinfected benchtop of a BSL-2 lab 
(June to August 2016); 55 samples were fortified with a human-derived fortifier and 2 samples were fortified with a 
bovine-derived fortifier. LAMINAR represents samples cultured in a laminar airflow cabinet of a BSL-2 lab 
(January 2017); the 20 fortified samples were all fortified with a bovine-derived fortifier. CFU = colony forming 
unit per 0.1mL of sample; HPDHM  Holder pasteurized donor human milk. 
 
Table 3. Prevalence of growth at each 24-hour interval by fortifier type and study phase 
 Unfortified Fortified P value 
BENCH    
Total number of HPDHM samples 16 57  
Total number of timepoints 73 248  
Timepoints with growth, n (%) 23 (31.5) 89 (35.9) 0.577 
Prevalence of any growth by time   >0.24 
Time 0 0 (1.4) 8 (3.2)  
Time 24 8 (11.0) 21 (8.5)  
Time 48 5 (6.9) 19 (7.7)  
Time 72 6 (8.2) 24 (9.7)  
Time 96 3 (4.1) 17 (6.9)  
LAMINAR    
Total number of HPDHM samples 20 20  
Total number of timepoints 100 100  
Timepoints with growth, n (%) 8 (8.0) 6 (6.0) 0.783 
Prevalence of any growth by time   >0.24 
Time 0 4 (4.0) 1 (1.0)  
Time 24 1 (1.0) 3 (3.0)  
Time 48 0 (0.0) 0 (0.0)  
Time 72 2 (2.0) 2 (2.0)  
Time 96 1 (1.0) 0 (0.0)  
Data represent quantities (%) of timepoints with any bacterial growth. Differences in categorical classifications were 
evaluated using a Fisher exact test. In BENCH (June to August 2016), samples were cultured on a disinfected 
benchtop and 55 samples were fortified with a human-derived fortifier and 2 samples were fortified with a bovine-
derived fortifier. In LAMINAR (January 2017), samples were cultured under a laminar airflow hood and the 20 




Our study is the first to address the combined effects of extended refrigeration storage and 
fortification with both bovine and human milk-derived fortifiers in “real life NICU” not 
laboratory settings. In our study, we observed sporadic growth of common skin bacteria in 
unfortified and fortified HPDHM. Importantly, we observed higher bacterial growth when 
culturing on a benchtop than when culturing under a laminar hood. Using a disinfected 
laboratory benchtop, 5.7% (37/640) of the cultures contained 6 or more CFUs, which would be 
indicative of milk discarding as per HMBANA guidelines, whereas none (0/400) of the cultures 
under a laminar hood exhibited this magnitude of bacterial growth. Cohen et al reported 
culturing HPDHM under sterile conditions and finding no growth in unfortified HPDHM at 24 to 
122 hours postthawing, but 33% (2/6) of HPDHM with a powdered bovine fortifier were 
bacterial culture-positive (7). Vickers et al (8) and Meng et al (9) who studied bacterial growth 
during storage in a laboratory setting, support Cohen's finding of no bacterial growth in 
unfortified HPDHM for 4 to 7 days of refrigerated storage. 
 
It has been reported that powdered infant formulas may expose infants to pathogenic bacteria (11). 
The fortifiers used in this study were liquid fortifiers, which may explain the lower rate of 
positive cultures we observed in BENCH (112/496, 23%) and LAMINAR environments (6/200, 
3%) as compared with those reported by Cohen et al (2/6, 33%), where a powdered fortifier was 
used. In addition, this study was a time line investigation where the majority of bacterial growth 
was not systemic, but sporadic and apparently unrelated to the longer storage times. Meng et al 
reported that bacteria introduced into HPDHM through exposure to the microbiota in the infant 
mouth through cup or bottle feeding decreased during refrigerated storage (9), which is likely 
because of antimicrobial proteins that are partially preserved during Holder pasteurization (12). 
This may explain why the bacterial growth that we observed in our study was sporadic in nature 
and did not increase with time. 
 
In a benchtop environment, 56% of the samples (41/73) had growth at 1 or fewer time points, 
and the maximum growth density was too many CFUs to be effectively counted. In contrast, in a 
laminar flow hood, 97.5% of the samples (39/40) had growth in 1 or fewer time points, and the 
maximum growth density was 1 CFU. The distinct results observed between the 2 culture 
environments warrants some discussion. The lower growth rates seen in LAMINAR could be the 
result of the different laboratory culture environments where a laminar flow hood would reduce 
external sample contamination. In addition, in LAMINAR an acid fortifier was added, which 
could also aid in reduction of bacterial growth. When limiting our analysis to just the unfortified 
samples, which were used in both the BENCH and LAMINAR study arms, we observed a 
significant difference in the percentage of cultures with any growth between BENCH (20%, 
29/144) and LAMINAR (4%, 8/200), which was statistically significant (P < 0.0001), suggesting 
that the laboratory plating environments may have contributed to the observed differences 
between phases. It is also possible that different milk technicians and nurses during the 2 study 
periods were handling the milk differently, thus contributing to differences that were observed. It 
is reassuring that even if bacteria might be introduced during handling, they did not demonstrate 
a continuous consistent or increasing growth patterns. 
 
Information on the impact of fortification on other characteristics of HPDHM during 
prolonged storage is limited and is an important area of future research. Donovan et al (13) studied 
the impact of an acidic and a neutral bovine-based fortifier on mother's milk and HPDHM over 
24 hours of refrigerated storage and reported changes in protein, lipase activity, pH, and 
osmolality. More research is warranted into how different fortifier types impact the nutrients, 
bioactive factors, and physical properties of HPDHM. Although our study suggests HPDHM 
inhibits bacterial growth in both unfortified and fortified samples during 96 hours of 
refrigerated storage, evidence is emerging that retort-processed shelf-stable human milk has 
significantly lower retention of antimicrobial proteins than HPDHM; therefore, more research is 
warranted into appropriate storage of human milk products that have been pasteurized using 




The use of 2 different laboratory plating environments is a limitation of this study. We could not 
compare results between BOV and HUM fortifiers because of the use of different plating 
environments; therefore, more research is warranted to see if HUM fortifiers produce low rates 
of bacterial growth when cultured under a laminar hood. After 24 hours of storage, the samples 
were only accessed once a day, thus greatly reducing the multiple nurse-exposure points for 
additional study days. Most samples cultured on a benchtop did not have a baseline 
measurement, at time 0, thus, 1 could not establish growth levels at the time the HPDHM was 
considered appropriate for clinical use. Where such baseline data was available, all samples were 
cultured under a laminar hood and there was very limited and sporadic growth of common skin 
bacteria and neither fortifier status nor storage time were significantly associated with bacterial 





This is the first large-scale study of the storage of fortified HPDHM in a clinical setting and 
contributes to the growing body of evidence regarding the refrigerated storage of HPDHM. Our 
research suggests that unfortified and fortified Holder pasteurized donor human milk can remain 
free of pathogenic bacterial growth, with limited presence of common skin microbiota, for up to 
96 hours of refrigerated storage when appropriate handling techniques are used in the feeding 
preparation room and laboratory. Our study supports the recently updated HMBANA guidelines 
for extending refrigeration storage time of defrosted HPHDM to 48 hours (6). More research is 
needed into how fortification type and storage time impact other factors in Holder 
pasteurized donor human milk including bioactive factors, micronutrients and macronutrients, 
and physical properties of the milk. More research is also warranted regarding the impact of 
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